查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1810921

2025年全球吸入性皮質類固醇設備市場報告

Inhaler Corticosteroid Device Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

吸入式皮質類固醇設備市場預計將在未來幾年強勁成長，到2029年將達到217.7億美元，複合年成長率為6.6%。預測期內的成長動力包括呼吸系統疾病的增加、呼吸健康意識的增強、對呼吸技術的大量投資、對健康教育的重視程度的提高以及吸煙成癮的增加。預計影響這一時期的關鍵趨勢包括智慧技術的採用、聯合治療的開發、能夠即時監控的數位吸入器的引入、吸入器設計的進步以及數據分析在吸入器設備中的應用。

預計呼吸系統疾病盛行率的上升將在未來幾年推動吸入性皮質類固醇裝置市場的成長。呼吸系統疾病包括影響肺部和呼吸道的多種疾病，會損害正常和有效的呼吸。呼吸系統疾病的增加歸因於空氣污染的加劇，人們暴露在有害顆粒中，這些顆粒會損害肺組織並引發氣喘和支氣管炎等慢性疾病。吸入性皮質類固醇裝置透過將抗發炎藥物直接輸送到肺部來治療呼吸系統疾病，有助於減輕發炎並改善呼吸。例如，2025 年 6 月，英國健康改善和消除不平等署報告稱，2024 會計年度，英格蘭因呼吸系統疾病緊急住院的人數為 854,922 人，相當於每 100,000 人口中有 1,428 人（範圍為 1,424 至 1,432 人），比上一年成長 7%。因此，呼吸系統疾病的日益流行正在刺激吸入性皮質類固醇裝置市場的擴張。

吸入性皮質類固醇裝置市場的主要企業正致力於推出創新解決方案，例如沙丁胺醇和Budesonide複方急救吸入器，以提高治療效果並透過單一裝置為患者提供更便捷的雙重作用療法。沙丁胺醇和Budesonide複方急救吸入器使用支氣管擴張劑（沙丁胺醇）快速打開氣道，並使用皮質類固醇（Budesonide）減輕炎症，從而通過單一裝置快速緩解症狀並長期控制氣喘。例如，2024 年 1 月，英國製藥公司阿斯特捷利康公司推出了 AIRSUPRA，這是第一個也是唯一一個獲得 FDA核准的用於成年氣喘患者的沙丁胺醇和Budesonide複方急救吸入器。這種吸入藥物旨在按需使用，以緩解急性支氣管收縮症狀並減少氣道炎症，從而降低嚴重氣喘發作的風險。這種新方法將短效BETA-2促效劑（沙丁胺醇）和吸入性皮質類固醇（Budesonide）結合在一個吸入器中，並根據臨床試驗核准，證明了其在預防氣喘發作方面優於單獨使用沙丁胺醇。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球吸入性皮質類固醇設備：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球吸入性皮質類固醇設備市場：成長率分析
  • 全球吸入性皮質類固醇設備市場表現：規模與成長，2019-2024
  • 全球吸入性皮質類固醇設備市場預測：規模與成長，2024-2029 年，2034 年
  • 全球吸入性皮質類固醇設備：總目標市場（TAM）

第6章市場區隔

  • 全球吸入性皮質類固醇設備市場（按產品類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 定量吸入器
  • 乾粉吸入器
  • 緩霧吸入器
  • 全球吸入性皮質類固醇設備市場（依處方類型、實際及預測），2019-2024 年、2024-2029 年、2034 年
  • Fluticasone propionate
  • Budesonide
  • 倍氯米松
  • 糠酸Mometasone
  • 全球吸入性皮質類固醇設備市場：按分銷管道、實際數據及預測，2019-2024 年、2024-2029 年、2034 年
  • 網路藥局
  • 零售藥局
  • 直銷
  • 醫院藥房
  • 全球吸入性皮質類固醇設備市場：按應用、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 氣喘
  • 慢性阻塞性肺病（COPD）
  • 其他用途
  • 全球吸入性皮質類固醇設備市場（依最終用戶、實際及預測）2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 居家護理
  • 專科診所
  • 其他最終用戶
  • 全球吸入性皮質類固醇設備市場：按定量噴霧吸入器細分（按類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 傳統定量吸入器
  • 呼吸驅動定量吸入器
  • 帶有整合墊片的定量吸入器
  • 全球吸入性皮質類固醇設備市場：乾粉吸入器細分（按類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 單劑量乾粉吸入器
  • 多劑量乾粉吸入器
  • 儲藥式乾粉吸入器
  • 全球吸入性皮質類固醇設備市場：緩霧吸入器細分市場（按類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 手動緩霧吸入器
  • 電池供電的緩霧吸入器

第7章 區域和國家分析

  • 全球吸入性皮質類固醇設備市場：區域分析、預測及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球吸入性皮質類固醇設備市場：國家/地區、實際資料及預測（2019-2024 年、2024-2029 年、2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 吸入性皮質類固醇設備市場：競爭格局
  • 吸入性皮質類固醇設備市場：公司簡介
    • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
    • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Teijin Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Aurobindo Pharma Limited
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • Hikma Pharmaceuticals PLC
  • Amneal Pharmaceuticals Inc.
  • Mundipharma International Limited
  • Lupin Limited
  • Zydus Lifesciences Limited
  • Recipharm AB
  • Glenmark Pharmaceuticals Limited
  • Orion Corporation
  • Beximco Pharmaceuticals Limited
  • PARI Medical Holding GmbH

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年吸入性皮質類固醇設備市場：提供新機會的國家
  • 2029年吸入性皮質類固醇設備市場：細分市場帶來新機會
  • 吸入性皮質類固醇設備市場 2029：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r37023

An inhaler corticosteroid device is a specialized medical instrument designed to deliver anti-inflammatory corticosteroid medication directly into the lungs. This targeted delivery reduces swelling and irritation in the airways caused by chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By acting locally in the lungs, these devices help control and prevent symptoms like wheezing, shortness of breath, and coughing, while limiting the systemic side effects often associated with oral corticosteroids.

The primary types of inhaler corticosteroid devices include metered-dose inhalers, dry powder inhalers, and soft mist inhalers. Metered-dose inhalers (MDIs) are portable devices that release a precise, measured dose of medication into the lungs as an aerosol. These inhalers use various drug formulations such as fluticasone propionate, budesonide, beclomethasone, and mometasone furoate. They are distributed through online and retail pharmacies, direct sales, and hospital pharmacies. These devices are widely used for managing conditions like asthma and COPD, with end users including hospitals, home care providers, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The inhaler corticosteroid device market research report is one of a series of new reports from The Business Research Company that provides inhaler corticosteroid device market statistics, including inhaler corticosteroid device industry global market size, regional shares, competitors with an inhaler corticosteroid device market share, detailed inhaler corticosteroid device market segments, market trends and opportunities, and any further data you may need to thrive in the inhaler corticosteroid device industry. This inhaler corticosteroid device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhaler corticosteroid device market size has grown strongly in recent years. It will grow from $15.75 billion in 2024 to $16.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period was driven by rising healthcare spending, a growing elderly population, favorable government policies, ongoing research and development efforts, and higher disposable incomes.

The inhaler corticosteroid device market size is expected to see strong growth in the next few years. It will grow to $21.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth during the forecast period is driven by an increase in respiratory disorders, heightened awareness of respiratory health, substantial investments in respiratory technologies, an expanding focus on health education, and a rise in smoking addiction. Key trends expected to influence this period include the adoption of smart technologies, development of combination therapies, introduction of digital inhalers with real-time monitoring, advancements in inhaler design, and the use of data analytics in inhaler devices.

The rising prevalence of respiratory diseases is expected to drive the growth of the inhaler corticosteroid device market in the coming years. Respiratory diseases encompass a variety of conditions affecting the lungs and airways, which impair proper and efficient breathing. The increase in respiratory diseases is attributed to growing air pollution, exposing people to harmful particles that damage lung tissue and trigger chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices treat respiratory diseases by delivering anti-inflammatory medication directly to the lungs, helping to reduce inflammation and improve breathing. For example, in June 2025, the UK's Office for Health Improvement and Disparities reported that in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases, corresponding to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population-a 7% increase compared to the previous year. Therefore, the growing prevalence of respiratory diseases is fueling the expansion of the inhaler corticosteroid device market.

Leading companies in the inhaler corticosteroid device market are focusing on launching innovative solutions, such as rescue inhalers that combine albuterol and budesonide to improve treatment efficacy and provide patients with a more convenient, dual-action therapy within a single device. An inhaler combining albuterol and budesonide is a dual-action rescue inhaler that delivers both a bronchodilator (albuterol) to rapidly open airways and a corticosteroid (budesonide) to reduce inflammation, offering quick symptom relief and long-term asthma control in one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical company, introduced AIRSUPRA, the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is intended for as-needed use to relieve acute bronchoconstriction symptoms and reduce airway inflammation, thereby lowering the risk of severe asthma attacks. It represents a novel approach by combining a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, with approval based on clinical trials demonstrating its superiority over albuterol alone in preventing asthma exacerbations.

In March 2022, Sandoz Group AG, a Switzerland-based company specializing in generic pharmaceuticals and biosimilars, acquired Coalesce Product Development Limited for an undisclosed amount. This acquisition aims to strengthen Sandoz's position in developing and delivering complex, high-quality respiratory therapies by incorporating Coalesce's advanced expertise in innovative drug delivery device design and manufacturing. This supports Sandoz's broader strategy to expand its value-added medicines portfolio and reinforce its commitment to patient-focused, integrated treatment solutions. Coalesce Product Development Limited is a UK-based medical device company specializing in designing and developing respiratory drug delivery devices, including inhalers for inhaled corticosteroids.

Major players in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH, and Kos Pharmaceuticals Inc.

North America was the largest region in the inhaler corticosteroid device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhaler corticosteroid device report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inhaler corticosteroid device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhaler corticosteroid device market consists of sales of nebulizer solutions, manual soft mist inhalers, conventional metered-dose inhalers, and combination inhalers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhaler Corticosteroid Device Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhaler corticosteroid device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhaler corticosteroid device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The inhaler corticosteroid device market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Metered-Dose Inhalers; Dry Powder Inhalers; Soft Mist Inhalers
  • 2) By Formulation Type: Fluticasone Propionate; Budesonide; Beclomethasone; Mometasone Furoate
  • 3) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Direct Sales; Hospital Pharmacies
  • 4) By Application: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Other Applications
  • 5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Subsegments:
  • 1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers; Breath-Actuated Metered-Dose Inhalers; Spacer-Integrated Metered-Dose Inhalers
  • 2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers; Multi-Dose Dry Powder Inhalers; Reservoir Dry Powder Inhalers
  • 3) By Soft Mist Inhalers: Manual Soft Mist Inhalers; Battery-Operated Soft Mist Inhalers
  • Companies Mentioned: AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Teijin Pharma Limited; Sun Pharmaceutical Industries Limited; Aurobindo Pharma Limited; Chiesi Farmaceutici S.p.A.; Cipla Limited; Hikma Pharmaceuticals PLC; Amneal Pharmaceuticals Inc.; Mundipharma International Limited; Lupin Limited; Zydus Lifesciences Limited; Recipharm AB; Glenmark Pharmaceuticals Limited; Orion Corporation; Beximco Pharmaceuticals Limited; PARI Medical Holding GmbH; Kos Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inhaler Corticosteroid Device Market Characteristics

3. Inhaler Corticosteroid Device Market Trends And Strategies

4. Inhaler Corticosteroid Device Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Inhaler Corticosteroid Device Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Inhaler Corticosteroid Device PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Inhaler Corticosteroid Device Market Growth Rate Analysis
  • 5.4. Global Inhaler Corticosteroid Device Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Inhaler Corticosteroid Device Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Inhaler Corticosteroid Device Total Addressable Market (TAM)

6. Inhaler Corticosteroid Device Market Segmentation

  • 6.1. Global Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metered-Dose Inhalers
  • Dry Powder Inhalers
  • Soft Mist Inhalers
  • 6.2. Global Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fluticasone Propionate
  • Budesonide
  • Beclomethasone
  • Mometasone Furoate
  • 6.3. Global Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Online Pharmacies
  • Retail Pharmacies
  • Direct Sales
  • Hospital Pharmacies
  • 6.4. Global Inhaler Corticosteroid Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Other Applications
  • 6.5. Global Inhaler Corticosteroid Device Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users
  • 6.6. Global Inhaler Corticosteroid Device Market, Sub-Segmentation Of Metered-Dose Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Conventional Metered-Dose Inhalers
  • Breath-Actuated Metered-Dose Inhalers
  • Spacer-Integrated Metered-Dose Inhalers
  • 6.7. Global Inhaler Corticosteroid Device Market, Sub-Segmentation Of Dry Powder Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Single-Dose Dry Powder Inhalers
  • Multi-Dose Dry Powder Inhalers
  • Reservoir Dry Powder Inhalers
  • 6.8. Global Inhaler Corticosteroid Device Market, Sub-Segmentation Of Soft Mist Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Manual Soft Mist Inhalers
  • Battery-Operated Soft Mist Inhalers

7. Inhaler Corticosteroid Device Market Regional And Country Analysis

  • 7.1. Global Inhaler Corticosteroid Device Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Inhaler Corticosteroid Device Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inhaler Corticosteroid Device Market

  • 8.1. Asia-Pacific Inhaler Corticosteroid Device Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inhaler Corticosteroid Device Market

  • 9.1. China Inhaler Corticosteroid Device Market Overview
  • 9.2. China Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inhaler Corticosteroid Device Market

  • 10.1. India Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inhaler Corticosteroid Device Market

  • 11.1. Japan Inhaler Corticosteroid Device Market Overview
  • 11.2. Japan Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inhaler Corticosteroid Device Market

  • 12.1. Australia Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inhaler Corticosteroid Device Market

  • 13.1. Indonesia Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inhaler Corticosteroid Device Market

  • 14.1. South Korea Inhaler Corticosteroid Device Market Overview
  • 14.2. South Korea Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inhaler Corticosteroid Device Market

  • 15.1. Western Europe Inhaler Corticosteroid Device Market Overview
  • 15.2. Western Europe Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inhaler Corticosteroid Device Market

  • 16.1. UK Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inhaler Corticosteroid Device Market

  • 17.1. Germany Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inhaler Corticosteroid Device Market

  • 18.1. France Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inhaler Corticosteroid Device Market

  • 19.1. Italy Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inhaler Corticosteroid Device Market

  • 20.1. Spain Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inhaler Corticosteroid Device Market

  • 21.1. Eastern Europe Inhaler Corticosteroid Device Market Overview
  • 21.2. Eastern Europe Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inhaler Corticosteroid Device Market

  • 22.1. Russia Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inhaler Corticosteroid Device Market

  • 23.1. North America Inhaler Corticosteroid Device Market Overview
  • 23.2. North America Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inhaler Corticosteroid Device Market

  • 24.1. USA Inhaler Corticosteroid Device Market Overview
  • 24.2. USA Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inhaler Corticosteroid Device Market

  • 25.1. Canada Inhaler Corticosteroid Device Market Overview
  • 25.2. Canada Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inhaler Corticosteroid Device Market

  • 26.1. South America Inhaler Corticosteroid Device Market Overview
  • 26.2. South America Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inhaler Corticosteroid Device Market

  • 27.1. Brazil Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inhaler Corticosteroid Device Market

  • 28.1. Middle East Inhaler Corticosteroid Device Market Overview
  • 28.2. Middle East Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inhaler Corticosteroid Device Market

  • 29.1. Africa Inhaler Corticosteroid Device Market Overview
  • 29.2. Africa Inhaler Corticosteroid Device Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Inhaler Corticosteroid Device Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Inhaler Corticosteroid Device Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inhaler Corticosteroid Device Market Competitive Landscape And Company Profiles

  • 30.1. Inhaler Corticosteroid Device Market Competitive Landscape
  • 30.2. Inhaler Corticosteroid Device Market Company Profiles
    • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Inhaler Corticosteroid Device Market Other Major And Innovative Companies

  • 31.1. Teijin Pharma Limited
  • 31.2. Sun Pharmaceutical Industries Limited
  • 31.3. Aurobindo Pharma Limited
  • 31.4. Chiesi Farmaceutici S.p.A.
  • 31.5. Cipla Limited
  • 31.6. Hikma Pharmaceuticals PLC
  • 31.7. Amneal Pharmaceuticals Inc.
  • 31.8. Mundipharma International Limited
  • 31.9. Lupin Limited
  • 31.10. Zydus Lifesciences Limited
  • 31.11. Recipharm AB
  • 31.12. Glenmark Pharmaceuticals Limited
  • 31.13. Orion Corporation
  • 31.14. Beximco Pharmaceuticals Limited
  • 31.15. PARI Medical Holding GmbH

32. Global Inhaler Corticosteroid Device Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inhaler Corticosteroid Device Market

34. Recent Developments In The Inhaler Corticosteroid Device Market

35. Inhaler Corticosteroid Device Market High Potential Countries, Segments and Strategies

  • 35.1 Inhaler Corticosteroid Device Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Inhaler Corticosteroid Device Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Inhaler Corticosteroid Device Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer